2015
Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer
Holmes D, Colfry A, Czerniecki B, Dickson-Witmer D, Francisco Espinel C, Feldman E, Gallagher K, Greenup R, Herrmann V, Kuerer H, Malik M, Manahan E, O’Neill J, Patel M, Sebastian M, Wheeler A, Kass R. Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer. Annals Of Surgical Oncology 2015, 22: 3184-3190. PMID: 26224406, DOI: 10.1245/s10434-015-4753-3.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic therapyClinical stage IIInvasive breast cancerBreast cancerSystemic therapyAxillary imagingPractice guidelinesStage IIPurposeThe American SocietyAdvanced breast cancerOptimal patient selectionExtent of diseaseSentinel node biopsyBreast-conserving surgeryEvidence-based guidelinesGenetic testing resultsEfficient patient careSystemic stagingAxillary lesionsClinical responseNode biopsyPerioperative managementSurgical morbidityGuideline recommendationsPatient selection
2012
Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer.
Greenup R, Bardia A, Buckley J, Niemierko A, Camp M, Coopey S, Gadd M, Schapira L, Taghian A, Smith B, Specht M. Association of pathologic complete response following neoadjuvant chemotherapy with survival among young women with breast cancer. Journal Of Clinical Oncology 2012, 30: 1122-1122. DOI: 10.1200/jco.2012.30.15_suppl.1122.Peer-Reviewed Original ResearchPathologic complete responseNeoadjuvant chemotherapyOverall survivalBreast cancerComplete responseYoung womenAdjuvant chemotherapyHazard ratioHER-2Stage IYoung breast cancer patientsTriple-negative breast cancerNeo-adjuvant chemotherapyTiming of chemotherapyBreast cancer patientsState tumor registryFinal pathologic reviewDeath certificate dataNegative breast cancerValuable surrogate markerOS ratesPathologic reviewSystemic therapyTumor RegistryDeath Index